Phase II
Three biopharma companies recently shuttered their clinical programs after either their compounds failed clinical trials or interim futility analysis suggested they were unlikely to meet their clinical endpoints. Here’s a look.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for November 3, 2020.
The decision to halt critically ill patients was made in response to Regeneron’s independent safety board finding a potential safety signal and an unfavorable risk-benefit profile of the monoclonal antibody therapy in a subgroup of patients requiring high-flow oxygen or mechanical ventilation.
Novo Nordisk announced today that it has ended its development of the anti-IL-21 antibody NN9828 in combination with Victoza. The decision was made after analyzing Phase II clinical trial data in patients with Type 1 diabetes.
It was a particularly busy week for announcements about clinical trials, both related to COVID-19 and everything else. Here’s a look.
The positive findings were shared as part of the company’s Emergency Use Authorization submission for its investigational COVID-19 therapy.
Recent Greenphire data shows new participant enrollment up 85% since slump in April.
Eli Lilly is continuing their other trial in mild-to-moderate COVID-19 patients and stated they “remain confident … that bamlanivimab monotherapy may prevent progression of disease for those earlier in the course of COVID-19.”
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for October 27, 2020.
Treatment with FORMA Therapeutics’ investigational agent olutasidenib has shown promising efficacy and safety in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) and mutations in isocitrate dehydrogenase 1 (IDH1m).
PRESS RELEASES